Facebook
Twitter
LinkedIn

FAST Company

ARIZ Precision Medicine

At ARIZ Precision Medicine, we target epigenetic changes that occur early in cancerization with siRNA-based therapeutics delivered directly to tumor cells. This combination of drug payload and drug delivery system allows for “Dual Targeting” of the cancer cell results in a product that is very safe and potentially curable for the patient.